1. Pink Sheet
  3. >>US FDA Performance Tracker

For Amylyx AMX0035 Panel Review, US FDA Relied Heavily on Temporary Voting Members

 
• By Sue Sutter

Peripheral and Central Nervous System Drugs Advisory Committee has held two of FDA’s most closely watched meetings in recent years, but there was little overlap between the panel that reviewed Amylyx’s ALS drug and the one that evaluated Biogen’s aducanumab 16 months earlier.

FDA advisory committee member puzzle
• Source: Alamy

Many comparisons have been drawn between the US Food and Drug Administration’s review of two high-profile, neurodegenerative disease drugs – Amylyx Pharmaceuticals, Inc.’s AMX0035 (sodium phenylbutyrate/taurursodiol) for amyotrophic lateral sclerosis and Biogen, Inc./Eisai Co., Ltd.’s Alzheimer’s treatment Aduhelm (aducanumab-avwa).

Both drugs target devastating diseases with high unmet need and few therapeutic options

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers